AACR-NCI-EORTC 2015

Epizyme scientists presented the following work at the 2015 Molecular Targets conference in Boston, Massachusetts. (Files are in .pdf format)

Tazemetostat:

• EZH2 plays a critical role in B-cell maturation and in non-Hodgkin’s lymphoma: Interplay between EZH2 function and B-cell activation
• Advanced Image Analysis of H3K27 Trimethylation in Skin from Subjects Dosed with the EZH2 Inhibitor Tazemetostat
• Chromatin flow cytometry based quantification of cell type specific alterations in histone methylation states resulting from in vitro and in vivo EZH2 inhibitor treatment
• Preclinical and clinical evaluation of EZH2 inhibitors in models of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
• Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors

Pinometostat:

• Identification of biomarkers and pathways associated with response to DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemia

• Pinometostat, EPZ-5676, Enhances the Anti-Proliferative Activity of MAP Kinase Pathway Inhibitors in Cell Lines Less Sensitive to DOT1L inhibition

Research Platform:

• CRISPR Pooled Screening Identifies Differential Dependencies on Epigenetic Pathways

• A Medium-Throughput Single Cell CRISPR/Cas9 Assay to Assess Gene Essentiality

• Identification of a Novel Potent Selective SMYD3 Inhibitor with Oral Bioavailability